The First Affiliated Hospital of Soochow University is conducting a phase II trial investigating the use of an immunotherapy, known as anti-BCMA CAR-T cell therapy, for relapsed and refractory ITP. This type of therapy uses a genetically modified version of a patient’s T-cells (type of immune cell) to better fight cells that are responsible for producing autoantibodies. Eligible participants include refractory and relapsed ITP patients aged 18-65. Participants are ineligible to enrol if they have secondary ITP, history of thrombosis, cardiovascular disease, cancer, are pregnant, or have received CAR-T cell infusion in the 3 months prior to enrolment.
China
https://www.clinicaltrials.gov/ct2/show/NCT05315778?recrs=a&cond=Immune+Thrombocytopenia&draw=2
Unknown status